acquired immunodeficiency syndrome (AIDS) 223
  cancer risk 224
  see also HIV-related lymphomas; human immunodeficiency
  virus (HIV)
acute kidney injury (AKI) 97–98
adolescents 33
  see also pediatric lymphomas
adult T-cell leukemia/lymphoma (ATL) 215–220
  allogeneic HSCT 217
  conditioning regimen 217
  donor choice 217–218
  autologous HSCT 217
  case study 220
  clinical presentation 215
  diagnostic criteria 215–216
  graft-versus-ATL effect 218
  minimal residual disease follow-up 218
  subtypes 215, 218
  treatment 216
  algorithm 219
  recommendations 218–219
  supportive therapy 219
AGNIS software 18, 18
alemtuzumab 63, 137, 241
chronic lymphocytic leukemia/small lymphocytic lymphoma
  management 140
  post-transplant chemotherapy 143
  diffuse large B-cell lymphoma management 156
  follicular lymphoma management 128–129
  Hodgkin lymphoma management 182, 186
  peripheral T-cell lymphoma management 197, 200
allogeneic HSCT 25, 59, 105
  adult T-cell leukemia/lymphoma 217
  anaplastic large-cell lymphoma 39
  Burkitt lymphoma 27, 207–208
  care delivery for survivors 107
  children, adolescents, and young adults 35–42
  chronic lymphocytic leukemia/small lymphocytic
  lymphoma 137–140
complications 106–107
  anemia 117
  infections 117, 118–119
  risk factors 106–107, 106
  screening and prevention guidelines 107, 108–109
  thrombocytopenia 117
  see also graft-versus-host disease (GVHD)
conditioning see conditioning regimens
cutaneous T-cell lymphoma 241–244, 241
  relapse management 244
day zero 115
diffuse large B-cell lymphoma 26, 149–154
  after autograft failure 153–154
  refractory disease 154
  donor/stem cell sources 63–65, 88–89, 90
  bone marrow 88–89
  haploidentical transplantation 64–65, 91–92, 129–130,
  185, 242
  matched related donor 90
  matched unrelated donor 90–91, 129–130, 184–185, 242
  mismatched unrelated donor 91
  mobilized peripheral blood 88–89
  umbilical cord blood cells 64, 88, 92, 129, 185
first 100 days 115–119, 116
  conditioning regimen impact 116
  mortality 119
  return home 118–119
  time to engraftment 117
  follicular lymphoma 26–27, 127–130
  chemorefractory follicular lymphoma 131
  transformed follicular lymphoma 130
  versus autologous transplant 130
  follow-up schedule 106, 269
  historical background 7–10, 87
  HIV-related lymphomas 231–233
  Hodgkin lymphoma 26, 36–37, 179–185, 180
  earlier phase disease 184
  patients failing after autologous HSCT 181–182
  relapse management 186
Index

long-term survival 105–106
lymphoblastic lymphoma 38, 208–210
lymphoplasmacytic lymphoma 249, 251, 251
mantle cell lymphoma 27, 165, 166, 168–170, 169
relapse management 172
non-Hodgkin lymphoma 26–27, 40–41
peripheral T-cell lymphoma 27, 192–193, 196–199
relapse management 200
preparation 59–66
relapse management 172
primary CNS lymphoma 27
primary mediastinal large B-cell lymphoma 255
prognostic tools 27
rationale 87–88
vaccine strategies 65

Waldenström macroglobulinemia 249, 251, 251
anaplastic large-cell lymphoma (ALCL) 38–39, 191
ALK-negative 191, 196
ALK-positive 191, 193–195
anemia 112–113
angioimmunoblastic T-cell lymphoma (AITL) 196
antithymocyte globulin (ATG) 242
antiviral therapy
adult T-cell leukemia/lymphoma 216
highly active antiretroviral therapy (HAART) 223–224, 227, 231
apheresis 79–80
complications 82
arsenic trioxide 216
Asia-Pacific BMT Registry (APBMT) 15
aspergillosis 10
prophylaxis 96
atrial fibrillation 96–97
autologous HSCT 25
adult T-cell leukemia/lymphoma 217
anaplastic large-cell lymphoma 38–39
Burkitt lymphoma 27, 207
children, adolescents, and young adults 34–36, 34, 38–42
chronic lymphocytic leukemia/small lymphocytic lymphoma 138–139
complications 95–100, 99
anemia 112–113
availability of the blood products 96–97, 99
cardiovascular side effects 96–97, 99
graft failure 97, 99
infection 95–96, 96, 113
liver toxicity 98
mucositis 96
neurologic toxicity 98
pulmonary complications 97, 99
renal toxicity 97–98
secondary malignancies 98–99
thrombocytopenia 112–113
conditioning see conditioning regimens
day zero 111
diffuse large B-cell lymphoma 26, 149–153
refractory disease 153
relapsed disease 152
first 100 days 111–114, 112
conditioning regimen impact 112
mortality 114
returning home 114
time to engraftment 112–113
follicular lymphoma 26–27, 123–127
graft purging 126–127
relapsed disease 124–126, 126
transformed follicular lymphoma 130
versus allogeneic transplant 130
follow-up calendar 267
historical background 8–9
HIV-related lymphomas 226–229, 230
immunological recovery after transplant 229–230
Hodgkin lymphoma 9, 25–26, 36, 178–179
prognostic factors 178
relapse management 185–186
lymphoblastic lymphoma 38, 208
lymphoplasmacytic lymphoma 249–251, 250
mantle cell lymphoma 27, 165–168
first-line treatment results 166–168, 167, 168
prognosis 170, 171
relapse management 170–172
salvage treatment results 168
second transplantation after failure 171–172
non-Hodgkin lymphoma 8–9, 34, 40–41
peripheral T-cell lymphoma 27, 191–196
front-line therapy 193–195, 194
post-transplant relapse management 199–200
relapsed/refractory disease 195–196
preparation 47–53
see also conditioning regimens
primary CNS lymphoma 27
primary mediastinal large B-cell lymphoma 254–255
prognostic tools 27
Waldenström macroglobulinemia 249–251, 250
see also stem cell mobilization
B-cell receptor (BCR) 143
BCNU regimen 48–52
follicular lymphoma 125
see also chemotherapy
BEAM regimen 48–52
chronic lymphocytic leukemia/small lymphocytic lymphoma 139
diffuse large B-cell lymphoma 150–151
follicular lymphoma 125, 126
HIV-related lymphomas 227, 228
Hodgkin lymphoma 178, 182
see also chemotherapy
bendamustine 142, 156, 186, 200, 248–249
“Berlin” patient 232–233
bexarotene 240
bleeding risk 113, 117
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 16, 52, 65, 92
bone marrow transplantation 88
versus mobilized peripheral blood 88–89
bortezomib 59, 158, 248–249
brentuximab 41, 63, 185–187, 200, 241
British National Lymphoma Investigation 9
Bruton’s tyrosine kinase 143
Bu/Mel regimen 52
see also chemotherapy
Burkitt lymphoma 27, 205–208, 206
allogeneic HSCT 27, 207–208
reduced-intensity conditioning 208
autologous HSCT 27, 207
children, adolescents and young adults 39
HIV-related 207, 225–227
busulfan 48–49, 52, 64

*Candida* prophylaxis 96
cardiovascular side effects 96–97, 99
carfilzomib 158
CBV regimen 48, 49
diffuse large B-cell lymphoma 150
HIV-related lymphomas 226–227, 231
Hodgkin lymphoma 178–179
see also chemotherapy
Center for International Blood and Marrow Transplant Research (CIBMTR) 15, 21–23, 105
case example 21–22
data flow 18, 18
data quality 18
data reporting 16–18
challenges 17–18
registry structure 16
value for public 22
value for young investigators 22
working committees 16, 16
chemotherapy 112
adult T-cell leukemia/lymphoma 216
Burkitt lymphoma 207
chronic lymphocytic leukemia/small lymphocytic lymphoma 139, 140, 142
post-transplant chemotherapy 142–143
complications 95
everly toxicities 95–98, 112
late toxicities 98–100
diffuse large B-cell lymphoma 150–152, 158
relapse after transplantation 156
salvage chemotherapy response 150
follicular lymphoma 123–126, 128–129
chemorefractory patients 131
HIV-related lymphomas 225–228
Hodgkin lymphoma 178–179, 182
lymphoblastic lymphoma 37, 208
lymphoplasmacytic lymphoma 249
mantle cell lymphoma relapse management 170–171
mycosis fungoides 240–241
non-Hodgkin lymphoma 8–9, 26–27, 39
pediatric lymphomas 34, 37, 39, 42
peripheral T-cell lymphoma 193–197
relapse management after transplantation 199–200
post-transplant lymphoproliferative disorders 264
primary mediastinal large B-cell lymphoma 253–254
relapsed/refractory disease 255
rejection prevention 118
Sézary syndrome 240–241
traditional conditioning regimens 47–49
children 33
stem cell mobilization 82
see also pediatric lymphomas
chimeric antigen receptor (CAR) T-cell therapy 2, 41
chronic lymphocytic leukemia/small lymphocytic lymphoma 144

CHOP regimen
adult T-cell leukemia/lymphoma 216
chronic lymphocytic leukemia/small lymphocytic lymphoma 139
diffuse large B-cell lymphoma 158
follicular lymphoma 123, 124
HIV-related lymphomas 225, 226
lymphoplasmacytic lymphoma 249
peripheral T-cell lymphoma 191, 195, 197
primary mediastinal large B-cell lymphoma 253–254
see also chemotherapy
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 137–145
allogeneic HSCT 137, 138
outcome 139–140
reduced-intensity conditioning regimens 137, 138, 140
autologous HSCT outcome 138–139
case study 145
donor-derived CLL 142
novel therapies 143–145
relapse management after transplantation 140–143
everly versus late relapses 141
recommended treatment approaches 141–142
timing and preparation for transplantation 138
transplantation indications 137–138
Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) 27, 52, 150
competing risk data 19
conditioning regimens 47, 112, 115
allogeneic HSCT 59–66, 115
complications 116
autologous HSCT 47–53, 112
complications 95, 112
cutaneous T-cell lymphoma 242–243
dose intensity role 182–184
future directions 52–53
monoclonal antibody incorporation 49–52, 63
radioimmunotherapy 49–52, 51–52
novel agents 52
traditional regimens 47–49
see also myeloablative conditioning (MAC) regimens;
reduced-intensity conditioning (RIC) regimens; specific
lymphomas
Cox model 21
crizotinib 201
cutaneous T-cell lymphoma (CTCL) 239
allogeneic HSCT 241–244, 241
conditioning regimen 242–243
donor selection and stem cell source 242
GVHD prophylaxis 243
indications for 242
monitoring for recurrence 243–244
post-transplant infectious prophylaxis 243
relapse management 244
autologous HSCT 241
see also mycosis fungoides (MF); Sézary syndrome (SS)
C.W. Bill Young Cell Transplantation Program 16, 17
cyclophosphamide 8–9, 52, 60, 64
chronic lymphocytic leukemia/small lymphocytic lymphoma
management 139, 140
post-transplant chemotherapy 142
cutaneous T-cell lymphoma management 242
follicular lymphoma management 123–125, 128
HIV-related lymphoma management 227, 231
Hodgkin lymphoma management 178–179
stem cell mobilization regimens 79
T-cell depletion 91
see also CBV regimen; chemotherapy; CHOP regimen
cyclosporine 128, 182, 243
cytarabine 27
cytomegalovirus (CMV) reactivation 10, 96
diabetes mellitus 81
diffuse alveolar hemorrhage (DAH) 97
diffuse large B-cell lymphoma (DLBCL) 21–22, 26, 149–159
allogeneic HSCT 26, 149–150, 153–154
after autograft failure 153–154
conditioning regimen role 154
outcomes 155
reduced-intensity conditioning (RIC) regimens 26, 60, 154
refractory disease 154
autologous HSCT 26, 149–153
consolidation in first remission 152
refractory disease 153
relapsed disease 152
case study 158–159
children, adolescents and young adults 39
histologic transformation to DLBCL 27
HIV-related 225, 227
myeloablative conditioning 26, 154
novel therapies 157–158
post-transplantation disease monitoring 154–156
relapse management after transplantation 156–157
treatment algorithm 157
salvage chemotherapy response 150
timing and preparation for transplantation 150–151
transplantation indications 149–150
treatment algorithm 151
see also primary mediastinal large B-cell lymphoma
(PMBL)
dimethyl sulfoxide (DMSO) side effects 111
disease testing 73
donor sources 63–65, 72, 90
adult T-cell leukemia/lymphoma 217–218
chronic lymphocytic leukemia/small lymphocytic
lymphoma 138
follicular lymphoma 129–130
haploidentical transplantation 64–65, 91–92, 129–130, 185, 242
matched related donors 217, 242
matched unrelated donors 129, 184–185, 217, 242
mismatched unrelated donors 91
umbilical cord blood cells 64, 88, 92, 129, 185
donor-recipient matching see donor sources; HLA
matching
doxorubicin 241
drug fever 113, 117
endocrine side effects 99–100
engraftment 117–118
engraftment syndrome 97
enteropathy-associated T-cell lymphoma (EATL) 196
EPOCH regimen 39
diffuse large B-cell lymphoma 158
HIV-related lymphomas 225–226
see also chemotherapy
epratuzumab 158
Epstein–Barr virus (EBV) 41, 224
Burkitt lymphoma association 205–207
management strategies 261–264, 262
post-transplant lymphoproliferative disorders 259, 260, 261
EBV DNAemia and 261
prevention 262
etoposide 52, 60
  follicular lymphoma management 123–124
  stem cell mobilization regimens 79
  see also BEAM regimen; CBV regimen; chemotherapy
European Inter-Group for Childhood NHL (EICNHL) 39
European Society for Blood and Marrow Transplantation (EBMT) 9, 15, 53
  adult T-cell leukemia/lymphoma report 218
  data flow 18, 18
  data reporting 17–18
  evaluation see patient evaluation
febrile neutropenia 95
  management 96
filgrastim 77, 82
flavopiridol 144–145
fludarabine 8, 36–37, 64
  chronic lymphocytic leukemia/small lymphocytic lymphoma management 139, 140
  post-transplant chemotherapy 142
  cutaneous T-cell lymphoma management 242
  follicular lymphoma management 128, 129
  HIV-related lymphoma management 231
  peripheral T-cell lymphoma management 197
follicular lymphoma (FL) 26–27, 123–132
  allogeneic transplant 26–27, 127–130
  chemorefractory follicular lymphoma 131
  nonsibling donor 129–130
  reduced-intensity conditioning regimens 60–62
  versus autologous transplant 130
  autologous transplant 26–27, 123–127, 130
  consolidation for first remission 123–124
  graft purging 126–127
  relapsed follicular lymphoma 124–126, 126
  minimal residual disease detection 131
  post-transplant relapse 131
  transformed follicular lymphoma 130
  transplant recommendations 132
FormsNet™ reporting system 17
Foundation for the Accreditation of Cellular Therapy (FACT) 15
gemcitabine 52, 199, 241
gene therapy 233–234
graft purging 126–127
  graft-versus-host disease (GVHD) 7, 87–92, 118
  adult T-cell leukemia/lymphoma 217
  chronic GVHD 11, 89, 105
  Hodgkin lymphoma 181
  chronic lymphocytic leukemia/small lymphocytic lymphoma 138, 142
  cutaneous T-cell lymphoma 242–243
  prophylaxis 243
  follicular lymphoma 128–129
hepatic acute GVHD 11
HIV-infected patients 231–232
mature B-cell (MB) lymphomas 226–229, 230
  immunological recovery after transplant 229–230
  “Berlin” patient 232–233
  Burkitt lymphoma 207
  chemotherapy 225–226
  clinical presentation 225
  prognosis 225
  stem cell mobilization 229
  see also human immunodeficiency virus (HIV)
HLA matching 89–91, 90  
chronic lymphocytic leukemia/small lymphocytic lymphoma 138  
haploidentical transplantation 64–65, 91–92, 129–130, 185, 242  
historical background 8  
Hodgkin lymphoma 184–185  
outcome relationships 90–92  
Hodgkin lymphoma (HL) 25–26, 177–187  
allogenic HSCT 26, 36–37, 179–185, 180  
early phase disease 184  
increasing the pool of donors 184–185  
patients failing after autologous HSCT 181–182  
reduced-intensity conditioning regimens 36, 37, 63, 179–184, 181  
relapse management 186  
autologous HSCT 25–26, 36, 178–179  
historical background 9  
preparative regimen 178–179  
prognostic factors 178  
relapse management 185–186  
children, adolescents and young adults 34, 35–37  
debulking therapy 178  
HIV-related 224–227  
novel therapies 186–187  
post-transplantation disease monitoring 185  
relapsed disease 9, 35–37  
transplantation indications 177  
human immunodeficiency virus (HIV) 223, 224  
cancer risk 224  
gene therapy potential 233–234  
highly active antiretroviral therapy (HAART) 223–224, 227, 231  
see also HIV-related lymphomas  
human lymphotropic virus I (HTLV-I) 215, 218  
hyperviscosity syndrome 247–248  
see also Waldenström macroglobulinemia (WM)  
ibrutinomab 50, 63  
ibrutinib 22, 53, 59  
chronic lymphocytic leukemia/small lymphocytic lymphoma  
management 143  
lymphoplasmacytic lymphoma management 248–249, 250  
mantle cell lymphoma management 172  
idelalisib 143–144, 249, 250  
idiospathic pneumonia syndrome (IPA) 97  
immune escape 141  
infections 95, 96, 113  
opportunistic 10  
prophylaxis 95–96, 113, 117  
risk avoidance 114, 118–119  
ininfertility 100  
inotuzumab ozogamicin 53  
insurance approval 74  
interferon alpha (IFN) 216, 241  
International Bone Marrow Transplant Registry (IMBTR) 15  
International Prognostic Index (IPI) 191, 225, 254  
International Prognostic Scoring System for Waldenström Macroglobulinemia (IPSSWM) 248  
invasive fungal diseases 10  
Joint Accreditation Committee of ISCT and EBMT (JACIE) 15  
Kaplan–Meier survival curves 19  
Kaposi sarcoma (KS) 224  
lenalidomide 158, 172, 201  
lensogastim 78  
liver toxicity 98  
lymphoblastic lymphoma (LBL) 37–38, 205, 208–210, 209  
allogeneic HSCT 38, 208–210  
autologous HSCT 38, 208  
Lymphoma Working Committee 19  
lymphoplasmacytic lymphoma (LPL) 247  
clinical manifestations 247–248  
epidemiology 247  
HSCT role 249–251, 250  
autologous HSCT 249, 251, 251  
management at relapse 249–251  
novel agents 248–249, 250  
prognostic factors 248  
maintenance therapy 27  
mantle cell lymphoma (MCL) 27, 165–172  
allogeneic HSCT 27, 165, 166, 168–170  
outcome 169–170, 169  
reduced-intensity conditioning regimens 63, 169–170  
relapse management 172  
autologous HSCT 27, 165, 166–168  
first-line treatment results 166–168, 167, 168  
prognosis 170, 171  
relapse management 170–172  
salvage treatment results 168  
second transplantation after failure 171–172  
novel therapies 172  
post-transplantation disease monitoring 170  
timing and preparation for transplantation 166  
transplantation indications 165, 166  
melphalan 52, 231, 242  
methotrexate  
GVHD prevention 7, 11, 118, 243  
Hodgkin lymphoma management 179, 182  
lymphoplasmacytic lymphoma management 37  
mycosis fungoides management 241  
peripheral T-cell lymphoma management 196, 197  
see also chemotherapy
mogamulizumab 201
monoclonal antibodies 49, 63
  radioimmunotherapy 49–52, 51–52
  see also specific antibodies
monoclonal B-cell lymphocytosis (MBCL) 141
mucositis 96
mycophenolate mofetil 243
mycosis fungoides (MF) 239
  allogeneic HSCT see cutaneous T-cell lymphoma (CTCL)
  nontransplant therapies 240–241
  pathology 239
  staging 239–240, 240
myeloablative conditioning (MAC) regimens 60, 61, 115, 210
  adult T-cell leukemia/lymphoma 217
  children, adolescents and young adults 37, 38, 41–42
  chronic lymphocytic leukemia/small lymphocytic lymphoma 138
  cutaneous T-cell lymphoma 242
  diffuse large B-cell lymphoma 26, 154
  follicular lymphoma 127–128
  historical background 9–10
  Hodgkin lymphoma 26, 37
  lymphoblastic lymphoma 38, 210, 211
  peripheral T-cell lymphoma 195
  transplant-related mortality and 127–128
myelodysplastic syndrome/acute myelogenous leukemia (t-MDS/AML) 98
National Marrow Donor Program (NMDP) 15, 25, 90
neurologic toxicity 98
neutropenia 95–96
  management 96
non-Hodgkin lymphoma (NHL) 26–27
  allogeneic HSCT 26–27
  autologous HSCT 26–27
    historical background 8–9
  children, adolescents and young adults 34
  HIV-related 224–225
  see also specific types
nonmyeloablative (NMA) conditioning regimens 59, 91
  see also reduced-intensity conditioning (RIC) regimens
nonrelapse mortality (NRM) 35, 37, 60
  diffuse large B-cell lymphoma 154
  see also transplant-related mortality (TRM)
novel therapies 27–28
  see also specific lymphomas
obese patients 81
obinutuzumab 41, 59, 144, 158
ofatumumab 59, 143, 158
older patients 2, 25
  reduced-intensity regimens 115
opportunistic infections 10
oral mucositis assessment scale (OMAS) 96
organ function testing 73
patient education 73–74
patient evaluation 72–74
  data review 72
  disease testing 73
  organ function testing 73
  post-evaluation review 74
  preparation for 72–73
PD-1/PD-L1 pathway 53
pediatric lymphomas
  anaplastic large-cell lymphoma 38–39
  future directions 41–42
  Hodgkin lymphoma 35–37
  HSCT principles 34–35
  lymphoblastic lymphoma 37–38
  mature B-cell lymphomas 39–41
  proposed treatment paradigm 42
  pegfilgrastim 78, 82
  pentostatin 142
peripheral blood stem cells (PBSCs) 77
  guideline recommendations 192
  mobilized peripheral blood transplantation 88
  versus bone marrow 88–89
  transplantation indication 191–193
  see also stem cell mobilization
peripheral T-cell lymphoma (PTCL) 27, 191–201
  allogeneic HSCT 27, 192–193, 196–199
  relapse management 200
  angioimmunoblastic T-cell lymphoma (AITL) 196
  autologous HSCT 27, 191–192, 193–196
  front-line therapy 193–195, 194
  relapse management 199–200
  enteropathy-associated T-cell lymphoma (EATL) 196
  novel therapies 200–201
  post-transplant disease monitoring 199
  prognostic indices 191–192
  reduced-intensity regimens 193, 196–197, 198
  relapsed/refractory disease 193, 195–196
  skin involvement 239
  timing and preparation for transplantation 193
  see also adult T-cell leukemia/lymphoma (ATL)
phosphatidylinositol 3-kinase (PI3K) 143
phototherapy, mycosis fungoides/Sézary syndrome 240
pidilizumab 53
platelet transfusions 112, 117
plerixafor
  adverse effects 82
  stem cell mobilization 77, 79, 82–83
  poor mobilizers 80–82, 81
pneumonia 95, 113
  idiopathic pneumonia syndrome (IPA) 97
  Pneumocystis jirovecii pneumonia 96
post-transplant lymphoproliferative disorders (PTLD) 259–264
  clinical symptoms 260
diagnosis 261
  EBV association 259–264
  EBV-negative PTLD 260
  epidemiology 259
  pathogenesis 260
  prevention 262
  risk factors 260
  therapy 262–264
  T-lineage PTLD 260
pralatrexate 200–201, 241
preparative regimens see conditioning regimens
primary CNS lymphoma 27
  HIV-related 224
primary mediastinal large B-cell lymphoma (PMBL) 253–256
  allogeneic HSCT 255
  autologous HSCT 254–255
  case study 256
  first-line therapy 253–254
  prognostic factors 254
  relapsed/refractory disease treatment 255
Prognostic Index for PTCL (PIT score) 191–192
prognostic tools 27
pruritus 239
pulmonary complications 97, 99
  diffuse alveolar hemorrhage (DAH) 97
  pulmonary edema 97
see also pneumonia
radiation therapy 48–49
  chronic lymphocytic leukemia/small lymphocytic lymphoma 142
  cutaneous T-cell lymphoma 242
  total body skin electron beam radiation (TBSEB) 243
diffuse large B-cell lymphoma 26, 60, 154
  lymphoblastic lymphoma 37
  radioimmunotherapy 49–52, 51–52
see also total body irradiation (TBI)
red blood cell transfusions 112, 117
reduced-intensity conditioning (RIC) regimens 2, 59, 60–63, 62, 91
  adult T-cell leukemia/lymphoma 217
  Burkitt lymphoma 208
  children, adolescents, and young adults 36, 37, 42
  chronic lymphocytic leukemia/small lymphocytic lymphoma 137, 138, 140
  cutaneous T-cell lymphoma 242
diffuse large B-cell lymphoma 26, 60, 154
  follicular lymphoma 60–62, 128, 129
  historical background 10
  Hodgkin lymphoma 36, 37, 63, 179–184, 181
  mantle cell lymphoma 63, 169–170
  older patients 115
  peripheral T-cell lymphoma 193, 196–197, 198
  reduction of immunosuppression see withdrawal of immunosuppression (WIS)
  referral 71–72
  rejection see graft-versus-host disease (GVHD)
  renal toxicity 97–98, 100
  respiratory complications see pulmonary complications
  rituximab 49, 63
  adverse effects 63
  Burkitt lymphoma management 207
  chronic lymphocytic leukemia/small lymphocytic lymphoma management 139
  post-transplant therapy 143
  relapse management 140, 142
  combination chemotherapy 8–9, 26, 27
  diffuse large B-cell lymphoma management 150–152, 157–158
  relapse after transplantation 156
  follicular lymphoma management 124, 125, 127, 128, 130
  graft purging 127
  HIV-related lymphomas 225–226
  Hodgkin lymphoma relapse management 186
  lymphoplasmacytic lymphoma management 248, 249
  maintenance therapy 26, 27, 52–53
  mantle cell lymphoma management 167, 170
  post-transplant lymphoproliferative disorder management 261, 262
  primary mediastinal large B-cell lymphoma management 253–254
  radioimmunotherapy 49, 52
  targeted immunotherapy 27–28, 35, 39, 41
  romidepsin 201, 241
  secondary malignancies 98–99
  Sézary syndrome (SS) 239–244
  nontransplant therapies 240–241
  pathology 239
  staging 239–240, 240
see also cutaneous T-cell lymphoma (CTCL)
statistical methods 19–21
  adjusted comparison 21
  at-risk population definition 19
  competing risk data 19
  survival data 19
  time to event 19
  unadjusted comparison 19–21
  stem cell collection 79–80
  stem cell mobilization 77
  adverse effects 82
  children 82
  HIV-infected patients 229
  methods 77–79, 78
obese patients 81
poor mobilizers and mobilization failure 80–81
remobilization 81
risk factors 80
supermobilizers 79
Stem Cell Therapeutic Outcomes Database (SCTOD) 16
data reporting 16–17
Streptococcus viridans infections 96
stromal‐derived factor (SDF)‐1 77
supportive care 10–11
survival data 19
tacrolimus, GVHD prevention 11, 243
targeted immunotherapy 27–28, 35, 41–42
T‐cell based therapies 41
T‐cell depletion 91
follicular lymphoma management 128–129
T‐cell lymphoma see adult T‐cell leukemia/lymphoma (ATL);
cutaneous T‐cell lymphoma (CTCL); peripheral T‐cell lymphoma (PTCL)
temsirolimus 172
thrombocytopenia 82, 112–113, 117
bleeding risk 113, 117
thyroid side effects 99–100
tositumomab 50–52
diffuse large B‐cell lymphoma management 151
total body irradiation (TBI) 47, 48–49, 60
chronic lymphocytic leukemia/small lymphocytic lymphoma 139
cutaneous T‐cell lymphoma 242
diffuse large B‐cell lymphoma 150
follicular lymphoma 123–127
HIV‐related lymphomas 227, 231
Hodgkin lymphoma 178
mantle cell lymphoma 167
peripheral T‐cell lymphoma 195
see also radiation therapy
total body skin electron beam radiation (TBSEB) 243
transplant‐related mortality (TRM) 19, 35, 95, 138
diffuse large B‐cell lymphoma 26
follicular lymphoma 127–128
see also nonrelapse mortality (NRM)
umbilical cord blood cell transplantation 64, 88, 92
adult T‐cell lymphoma/lymphoma 217–218
follicular lymphoma 129
Hodgkin lymphoma 185
UV radiation therapy, mycosis fungoides/Sézary syndrome 240
vaccine strategies 65
Varicella zoster prophylaxis 96
vinorelbine 52
vorinostat 241
Waldenström macroglobulinemia (WM) 247
clinical manifestations 247–248
epidemiology 247
HSCT role 249–251, 250
allogeneic HSCT 249, 251, 251
prognostic factors 248, 248
withdrawal of immunosuppression (WIS)
chronic lymphocytic leukemia/small lymphocytic lymphoma 141
diffuse large B‐cell lymphoma 156–157
mantle cell lymphoma 172
post‐transplant lymphoproliferative disorders 262–264, 263
zeta‐chain‐associated protein (ZAP) 140
zidovudine 216, 223, 231